Your pop up blocker may be preventing the MarketSmith tool from opening.
Learn how to resolve this issue.
Company has 17 patents going for it. If you have some time to wait IMHO you will be rewarded.
Some notes from the 2Q release
"The Company continued to make progress in our ongoing ALS cell
therapy clinical trial in the second quarter of 2012," said Karl Johe,
PhD, Chairman of Neuralstem's Board of Directors and Chief Scientific
Officer. "With FDA approval, we are currently transplanting a cohort of
return patients that had previously received lumbar injections.
Patients 16 and 17 have now received cervical injections."
Johe continued, "The second quarter also saw the Phase Ib commencement
of the ongoing trial of our lead neurogenic small molecule compound,
NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib
tests the safety of escalating doses for a 28-day cycle."
President and CEO, Richard Garr, added, "During the quarter, we
increased the total number of owned or exclusively licensed worldwide
issued patents to 27. We continue to expand our intellectual property
in the field of regenerative medicine with an additional 44 pending
U.S. and foreign patent applications related to our stem cell
technologies and our small molecule compounds.
"Dr. Johe and I
would like to thank the ALS cell therapy investigators: University of
Michigan's Dr. Eva Feldman and Emory University's Dr. Jonathan Glass
and Dr. Nicolas Boulis, and Harvard's Dr. Maurizio Fava who helped to
design the NSI-189/MDD trial. We continue to thank our courageous
patients and their families," concluded Garr.
© 2013 MarketSmith, Incorporated. All Rights Reserved. MarketSmith® is a registered trademark of MarketSmith, Incorporated. All data provided by William O'Neil + Co. Incorporated unless otherwise noted.